Virogenetics Corporation

Other

University of Hawai'i

Pasteur Merieux Serums Et Vaccins

Charles De Taisne

Enzo Paoletti

James Tartaglia

Michel Albert Riviere

William I Cox

Jill Taylor

Steven E Pincus

Russell Robert Gettig

Keith J Limbach

Marion E Perkus

Elizabeth K Norton

Jean-Christophe Francis Audonnet

Gerard P Johnson

Sandra Chang

George Hui

John A Tine

Wasim A Siddiqui

Wasim A Siddigui

What is described is a recombinant poxvirus, such as vaccinia virus, containing foreign DNA from Plasmodium Merozoite Surface Antigen 1. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.

Malaria recombinant poxvirus vaccine

What is described is a recombinant poxvirus, such as vaccinia or canarypox virus, containing foreign DNA from Plasmodium such as coding for at least one of CSP, PfSSP2, LSA-1, LSA-1-repeatless, MSA-1, SERA, AMA-1, Pfs25, MSA-1 N-terminal p83 and MSA-1 C-terminal gp42. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. Preferred recombinants have attenuated virulence. In certain embodiments the vaccinia has deleted or disrupted the thymidine kinase gene, the hemorrhagic region, the A type inclusion body region, the host range gene region and, the large subunit, ribonucleotide reductase; and, contains coding sequences for CSP, PfSSP2, LSA-1-repeatless, MSA-1, SERA, AMA-1 and Pfs25. That embodiment is termed NYVAC-Pf7 and is a multicomponent, multistage vaccine since it codes for and expresses sporozoite proteins, liver stage proteins, blood stage proteins and, sexual stage proteins.

Malaria recombinant poxviruses

What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.

Growing community of inventors

Lyons, France

Charles De Taisne